As of 2025-12-20, the Relative Valuation of Madrigal Pharmaceuticals Inc (MDGL) is (276.90) USD. This relative valuation is based on P/E multiples. With the latest stock price at 591.02 USD, the upside of Madrigal Pharmaceuticals Inc based on Relative Valuation is -146.9%.
The range of the Relative Valuation is (282.12) - (322.86) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.2x - 25.4x | 25.2x |
| Forward P/E multiples | 18.1x - 25.4x | 18.3x |
| Fair Price | (282.12) - (322.86) | (276.90) |
| Upside | -147.7% - -154.6% | -146.9% |
| Date | P/E |
| 2025-12-17 | -42.90 |
| 2025-12-16 | -43.56 |
| 2025-12-15 | -44.03 |
| 2025-12-12 | -44.89 |
| 2025-12-11 | -44.88 |
| 2025-12-10 | -43.40 |
| 2025-12-09 | -43.51 |
| 2025-12-08 | -44.66 |
| 2025-12-05 | -45.35 |
| 2025-12-04 | -46.05 |
| 2025-12-03 | -45.55 |
| 2025-12-02 | -45.02 |
| 2025-12-01 | -45.51 |
| 2025-11-28 | -46.89 |
| 2025-11-26 | -47.21 |
| 2025-11-25 | -46.50 |
| 2025-11-24 | -46.18 |
| 2025-11-21 | -43.04 |
| 2025-11-20 | -42.58 |
| 2025-11-19 | -43.64 |
| 2025-11-18 | -43.91 |
| 2025-11-17 | -43.47 |
| 2025-11-14 | -41.57 |
| 2025-11-13 | -40.45 |
| 2025-11-12 | -41.55 |
| 2025-11-11 | -42.53 |
| 2025-11-10 | -38.95 |
| 2025-11-07 | -38.43 |
| 2025-11-06 | -38.38 |
| 2025-11-05 | -37.38 |
| 2025-11-04 | -34.93 |
| 2025-11-03 | -32.39 |
| 2025-10-31 | -32.90 |
| 2025-10-30 | -33.58 |
| 2025-10-29 | -33.12 |
| 2025-10-28 | -33.71 |
| 2025-10-27 | -34.23 |
| 2025-10-24 | -33.11 |
| 2025-10-23 | -33.29 |
| 2025-10-22 | -32.67 |
| 2025-10-21 | -33.78 |
| 2025-10-20 | -34.56 |
| 2025-10-17 | -34.47 |
| 2025-10-16 | -34.73 |
| 2025-10-15 | -34.05 |
| 2025-10-14 | -34.33 |
| 2025-10-13 | -33.60 |
| 2025-10-10 | -33.74 |
| 2025-10-09 | -33.64 |
| 2025-10-08 | -34.32 |